Patients
Moving beyond intent: Building more diverse clinical trials
Improving representation is not simply about increasing awareness or setting enrolment targets. It requires identifying and removing the barriers.
Oncology
Sponsored
Establishing ctDNA as a validated primary surrogate endpoint
Circulating tumour DNA (ctDNA) has emerged as a promising primary surrogate endpoint in solid tumour oncology.
Sales & Marketing
Why trust is becoming pharma’s most important visibility met...
Any gap between an AI-generated answer and a product’s approved profile carries consequences for prescribing decisions and patient safety.
R&D
CAMP4 on a new class of ASO in gene under expression
CAMP4 Therapeutics CFO Kelly Gold discusses developments in antisense oligonucleotides and CAMP4’s CMP-002 study
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
